Chapter 57. β2-Agonists

  1. Robert A. Stockley Professor1,
  2. Stephen I. Rennard Professor2,
  3. Klaus Rabe Professor3 and
  4. Bartolome Celli Professor4
  1. Malcolm Johnson

Published Online: 11 JAN 2008

DOI: 10.1002/9780470755976.ch57

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

How to Cite

Stockley, R. A., Rennard, S. I., Rabe, K. and Celli, B. (2007) β2-Agonists, in Chronic Obstructive Pulmonary Disease, Blackwell Publishing Ltd, Oxford, UK. doi: 10.1002/9780470755976.ch57

Author Information

  1. 1

    Professor of Medicine, Department of Medicine, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK

  2. 2

    Pulmonary & Critical Care Medicine Section, University of Nebraska Medical Center, 985125 Nebraska Medical Center, 800 South 42nd Street, Omaha, NE 68198-5300

  3. 3

    Dept of Pulmonology, Leiden Universtiy Medical Centre, Albinusdreef 2, C3-P, Postbox 9600, 2300 RC, Leiden, Netherlands

  4. 4

    Division of Pulmonary and Critical Care, St Elizabeth's Medical Centre, 736 Cambridge Street, Tufts University, Boston, MA 02135-2907

Publication History

  1. Published Online: 11 JAN 2008
  2. Published Print: 1 JAN 2007

ISBN Information

Print ISBN: 9781405122894

Online ISBN: 9780470755976



  • pathophysiology;
  • β2-agonists;
  • acute bronchospasm;
  • inflammatory cells;
  • mucociliary dysfunction


This chapter contains sections titled:

  • Mechanisms of action of β2-agonists

  • Effects of β2-agonists on airway inflammation

  • Effects of β2-agonists on the airway epithelium

  • Potential effects of 2-agonists on structural changes in COPD

  • Effects of 2-agonists on the systemic component of COPD

  • Clinical efficacy of 2-agonists in patients with COPD

  • Combination therapy with LABAs and corticosteroids

  • Combination of 2-agonists and anticholinergics

  • Combination of 2-agonists and theophylline

  • Safety of 2-agonists in COPD

  • Conclusions

  • Acknowledgement

  • References